TRIAL OF OSTEOPOROSIS PREVENTION IN RACIALLY DIVERSE PROSTATE CANCER PATIENTS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。骨质疏松症和相关的骨折是一个主要的公共卫生问题，因为相关的发病率，残疾，生活质量下降和死亡率。不幸的是，在卫生专业人员、患者和广大公众中，对前列腺癌雄激素剥夺男性患者骨质疏松症的预防或治疗普遍无知。例如，根据国家骨质疏松症基金会（1996年）公布的一项盖洛普调查，大多数美国男性认为骨质疏松症只是一种女性疾病。由于缺乏这方面的研究和证据，卫生专业人员也没有采取预防措施。在绝经后妇女中，治疗和/或预防骨质疏松症的药物选择包括碳酸钙/维生素D组合、雌激素替代疗法和口服双膦酸盐疗法等。同样的证据表明，在继发于慢性糖皮质激素治疗和甲状腺替代治疗的骨质疏松症男性和女性患者中，间歇性静脉注射双膦酸盐（帕米膦酸盐）治疗是有效的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Osteoporosis and associated fractures are a major public health concern because of related morbidity, disability, decreased quality of life and mortality. Unfortunately, ignorance about prevention or treatment of osteoporosis in male patients on androgen deprivation for prostate cancer is widespread among health professionals, patients and the public at large. For example, the majority of American men view osteoporosis solely as a woman's disease" according to a Gallup survey published by the National Osteoporosis Foundation (1996). Health professionals too have not taken preventive measures due to lack of research and evidence in this area. In postmenopausal women, pharmacological options for treating and/or preventing osteoporosis include Calcium carbonate/ vitamin D combinations, estrogen replacement therapy, and oral bisphosphonate therapy among others. Similarly evidence suggests that in osteoporosis secondary to chronic glucocorticoid therapy and thyroid replacement therapy in male and female patients, treatment with intermittent intravenous bisphosphonate (pamidronate) therapy is effective.